Company intelligence / Profile preview

Imuno Therapeutics

Leiden, South Holland, Netherlandsimunotx.com ↗

Ownership: Private
Employees: ~9
Development stage: Preclinical

Overview

Imuno Therapeutics has developed a highly targeted cancer therapy based on TCR-mimic antibodies. Their lead program has demonstrated strong safety and efficacy in preclinical or early-stage studies, with results shared at academic conferences. The company’s approach aims to deliver potent therapies for patients lacking effective treatment options, leveraging an innovative AI-driven discovery platform. They are engaging with larger pharmaceutical partners to advance their therapies toward patients.

Therapeutic areas: Oncology
Modalities: TCR-mimic antibodies (TCRm)immunotherapies leveraging AI and synthetic biology
Industry: Biotech

Partnerships

In discussions with larger pharma companies for potential partnerships/commercialization but none formally announced yet.

Beyond the preview

Go deeper on Imuno Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imuno Therapeutics.

Explore the full profile